Literature DB >> 27293986

Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.

Karolina Jablonska1, Jedrzej Grzegrzolka1, Marzenna Podhorska-Okolow1, Mariusz Stasiolek2, Bartosz Pula1, Mateusz Olbromski1, Agnieszka Gomulkiewicz1, Aleksandra Piotrowska1, Janusz Rys3, Aleksandra Ambicka3, Siew Hwa Ong4, Maciej Zabel5, Piotr Dziegiel6.   

Abstract

Many studies are dedicated to exploring the molecular mechanisms of chemotherapy-resistance in breast cancer (BC). Some of them are focused on searching for candidate genes responsible for this process. The aim of this study was typing the candidate genes associated with the response to standard chemotherapy in the case of invasive ductal carcinoma. Frozen material from 28 biopsies obtained from IDC patients with different responses to chemotherapy were examined using gene expression microarray, Real-Time PCR (RT-PCR) and Western blot (WB). Based on the microarray results, further analysis of candidate gene expression was evaluated in 120 IDC cases by RT-PCR and in 224 IDC cases by immunohistochemistry (IHC). The results were correlated with clinical outcome and molecular subtype of the BC. Gene expression microarray revealed Prolactin-Induced Peptide (PIP) as a single gene differentially expressed in BC therapy responder or non-responder patients (p <0.05). The level of PIP expression was significantly higher in the BC therapy responder group than in the non-responder group at mRNA (p=0.0092) and protein level (p=0.0256). Expression of PIP mRNA was the highest in estrogen receptor positive (ER+) BC cases (p=0.0254) and it was the lowest in triple negative breast cancer (TNBC) (p=0.0336). Higher PIP mRNA expression was characterized by significantly longer disease free survival (DFS, p=0.0093), as well as metastasis free survival (MFS, p=0.0144). Additionally, PIP mRNA and PIP protein expression levels were significantly higher in luminal A than in other molecular subtypes and TNBC. Moreover significantly higher PIP expression was observed in G1, G2 vs. G3 cases (p=0.0027 and p=0.0013, respectively). Microarray analysis characterized PIP gene as a candidate for BC standard chemotherapy response marker. Analysis of clinical data suggests that PIP may be a good prognostic and predictive marker in IDC patients. Higher levels of PIP were related to longer DFS and MFS but not with OS.

Entities:  

Keywords:  PIP; adjuvant chemotherapy; breast cancer

Year:  2016        PMID: 27293986      PMCID: PMC4889707     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  48 in total

1.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Authors:  Osvaldo Pontiggia; Rocio Sampayo; Diego Raffo; Andrea Motter; Ren Xu; Mina J Bissell; Elisa Bal de Kier Joffé; Marina Simian
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

2.  Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor.

Authors:  E Mueller-Holzner; V Fink; T Frede; C Marth
Journal:  Breast Cancer Res Treat       Date:  2001-09       Impact factor: 4.872

3.  [WHO classification of tumors of the breast].

Authors:  Feng Yang; Jinfeng Li
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2014-01

4.  Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.

Authors:  G Mazoujian; G S Pinkus; S Davis; D E Haagensen
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

5.  Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.

Authors:  Rohit Bhargava; Sushil Beriwal; David J Dabbs
Journal:  Am J Clin Pathol       Date:  2007-01       Impact factor: 2.493

6.  Immunohistochemical study with antibody to glycoprotein GCDFP-15 for metastatic lung cancer from breast cancer.

Authors:  Y Nonami; S Hisa; A Yamamoto; S Sasaguri; H Kiyoku; H Kurumaya
Journal:  J Cardiovasc Surg (Torino)       Date:  2001-08       Impact factor: 1.888

7.  Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.

Authors:  Lei Huo; Jinxia Zhang; Michael Z Gilcrease; Yun Gong; Yun Wu; Hong Zhang; Erika Resetkova; Kelly K Hunt; Michael T Deavers
Journal:  Histopathology       Date:  2012-09-11       Impact factor: 5.087

8.  Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.

Authors:  Ming-Hua Luo; Yu-Hua Huang; Yun-Bi Ni; Julia Y S Tsang; Siu-Ki Chan; Mu-Min Shao; Gary M Tse
Journal:  Hum Pathol       Date:  2013-01-17       Impact factor: 3.466

9.  Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.

Authors:  Jean-Louis Carsol; Sébastien Gingras; Jacques Simard
Journal:  Mol Endocrinol       Date:  2002-07

10.  A consensus prognostic gene expression classifier for ER positive breast cancer.

Authors:  Andrew E Teschendorff; Ali Naderi; Nuno L Barbosa-Morais; Sarah E Pinder; Ian O Ellis; Sam Aparicio; James D Brenton; Carlos Caldas
Journal:  Genome Biol       Date:  2006-10-31       Impact factor: 13.583

View more
  3 in total

1.  The Effect of Functional Mandibular Shift on the Muscle Spindle Systems in Head-Neck Muscles and the Related Neurotransmitter Histamine.

Authors:  Bing-Li Du; Jiang-Ning Li; Hong-Ming Guo; Song Li; Biao Liu
Journal:  J Craniofac Surg       Date:  2017-09       Impact factor: 1.046

2.  A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging.

Authors:  Georg Brunner; Achim Heinecke; Thomas M Falk; Beyhan Ertas; Norbert Blödorn-Schlicht; Hans-Joachim Schulze; Ludwig Suter; Jens Atzpodien; Carola Berking
Journal:  JNCI Cancer Spectr       Date:  2018-07-23

3.  Functional proteomics outlines the complexity of breast cancer molecular subtypes.

Authors:  Angelo Gámez-Pozo; Lucía Trilla-Fuertes; Julia Berges-Soria; Nathalie Selevsek; Rocío López-Vacas; Mariana Díaz-Almirón; Paolo Nanni; Jorge M Arevalillo; Hilario Navarro; Jonas Grossmann; Francisco Gayá Moreno; Rubén Gómez Rioja; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Paloma Main; Jaime Feliú; Purificación Martínez Del Prado; Pilar Zamora; Eva Ciruelos; Enrique Espinosa; Juan Ángel Fresno Vara
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.